In addition, this correlation is also supported by previous work that associated Emx2 and Wnt1 in the neural context [49] and found reduced Wnt pathway activity in the context of EMX2 overexpression in lung cancer, gastric cancer, glioblastoma, melanoma [20, 21, 50–52], and sarcomas such as Ewing's sarcoma, synovial sarcoma, leiomyosarcoma, osteosarcoma, and MPNST [37, 40, 53, 54]. This evidence concerns the gene EMX2 and synovial sarcoma.